Uganda & Gilead Sciences

Uganda: Uganda has confirmed imported Ebola cases from the Democratic Republic of the Congo, leading to heightened surveillance, travel restrictions, and the postponement of national events to prevent further spread.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Uganda: Uganda has reported cases of the Bundibugyo strain of Ebola, making it a focus for the World Health Organization's efforts to implement clinical trials for experimental treatments and vaccines.

Gilead Sciences: Gilead Sciences developed the antiviral remdesivir and experimental oral antiviral obeldesivir, both prioritized by the World Health Organization for treatment and prevention of the Bundibugyo strain of Ebola.

Uganda: Confirmed 20 cases and 2 deaths; implementing cross-border surveillance and response measures.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.

Uganda: Uganda>>> has reported confirmed Ebola cases linked to the outbreak in the Democratic Republic of the Congo>>>, leading to border closures and heightened surveillance efforts, while also expressing concern over the Uganda — Bundibugyo virus being named after one of its districts.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Uganda: Uganda has confirmed cases of Ebola linked to the outbreak in the Democratic Republic of the Congo, leading to border closures and quarantine measures. Its authorities have expressed unawareness of US-funded treatment centers.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

Uganda: Contained imported cases and declared itself Ebola-free; remains at risk due to cross-border spread.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.

Uganda: Uganda participated in the clinical trials that evaluated the efficacy of Lenacapavir.

Gilead Sciences: Gilead Sciences developed Lenacapavir and has committed to granting a voluntary manufacturing license to a South African company, which will allow for cheaper generic versions of the drug.

Uganda: Uganda>>> has reported confirmed cases and deaths linked to the Ebola outbreak, contributing to the regional concern that prompted the United States>>>'s quarantine plans.

Gilead Sciences: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.